

Supplementary data

Supplementary Figure 1 Number patients hospitalised for acute respiratory infections included in the surveillance in Quebec, Canada, by epi-week during the pre-pandemic (A) and pandemic (B) periods

Α



В



Note: Four hospitals participated during pre-pandemic period. Three hospitals participated during 2020-21 with periodic sampling by day of week. Four hospitals participated during 2021-22 with periodic sampling by day of week. The two additional hospitals are not presented.

Supplementary Figure 2 Surveillance flowchart by period*

Period	2012-2020 (pre-pandemic)	2020-2021 (first pandemic year)	2021-2022 (second pandemic year)
Number of swabbed patients	6,412	1,454	1,521
Exclusions:			
Refusal/unable to consent	68	NA	NA
Eligibility criteria not met	51	63	182
Enrolled before the surveillance period	0	26	52
Missed by nurses	25	NA	NA
Admitted less than 24 hours	18	2	16
COVID-19 patient transferred from another region ²	NA	222	NA
Health-care acquired ARI ³	364	145	54
Samples not received by LSPQ/insufficient volume	36	205	22
Other reason ⁴	18	0	25
Included in the analysis	5,832	791	1,170

^{*4} centers included

NA: not applicable

¹For example: symptoms related to another condition (i.e fever in urinary tract infection, cellulitis)

²Transfers from centers not designated to receive COVID-19 patients according to government mandate situated in regions not covered by participating hospitals outside the COVID-19 mandate

³Defined as: Onset of ARI symptoms >72 hours after admission

⁴For example: duplicate cases, medical chart not available.

Supplementary table 1 Timeline of SARS-CoV-2 epidemiology and main mitigation measures in Quebec (more details available at https://www.inspq.qc.ca/covid-19/donnees/ligne-du-temps).

Year	Date	Events
2020	February 23	Start of first wave
	March 13	Declaration of health emergency by the province of Quebec
	March 14	Cancellation of non-essential visits to long-term-care-facilities (LTCF) and
		hospitals; stay-at-home order for ≥70 years, physical distancing; closure of
		some public spaces, school and kindergartens closure
	March 18	International border closure
	March 18	LTCF and nursing homes lockdown, progressive closure of all services
		excepting those essential; restrictions of travel between some regions with
	April 15	check points at entry; cancellation of all summer festivals and activities Progressive opening of some sectors, easing of some measures
	July 11	End of first wave
	July 13	Mandatory use of masks or face covering in public transport
	July 18	Mandatory use of masks or face covering in public transport Mandatory use of masks or face covering in all public enclosed spaces
	August 20	Start of second wave
	September 8	Graded regional warning system in place
	September 11	Progressive tightening of measures
	December 14	Start of COVID-19 vaccination with LTCF residents and LTCF health-care
		workers (HCW) according to priority order
	December 25	Closure of non-essential businesses
	December 29	First detection of the B.1.1.7 variant (Alpha)
	December 31	Given limited number of COVID-19 vaccines, dose 1 is prioritized in order to
		rapidly achieve higher coverage in vulnerable groups
2021		Progressive easing of measures
	February 9	First detection of the B.1.351 variant (Beta)
	March 1	Vaccination extended to general population according to priority groups
	March 20	End of second wave
	March 21	Start of third wave
	March 25	Only one dose of vaccine may be administered to persons with prior COVID- 19 infection
	April 1	Special emergency measures in some regions
	April 26	First detection of the B.1.617 variant (Delta)
	May 18	50% of Quebec population ≥12 years received at least 1 dose
	June 6	75% of Quebec population ≥12 years received at least 1 dose
	July 17	End of third wave
	July 18	Start of forth wave
	September 1	Vaccination passport required for access to most public spaces
	September 28	Booster dose recommended for LTCF and nursing homes residents
	September 30	75% of Quebec population is adequately vaccinated
	November 1	6 months between booster dose and last dose received is recommended.
		Optimal interval between 1 st and 2 nd dose is 8 weeks
	November 15	Progressive easing of some measures

	November 16	Booster dose recommended to ≥70 years from community, persons who received a viral vector vaccine may receive a mRNA vaccine booster		
	November 24	Start of 5-11-year-olds vaccination Detection of omicron variant		
	November 29			
	December 4	End of forth wave		
	December 5 Start of fifth wave			
	December 20	Progressive tightening of measures, including curfew starting December 31 Booster dose advanced for all ≥ 60 years; interval between last dose and booster shortened from 6 to 3 months		
	December 29	Booster dose offered to essential workers followed-up by all population according to age groups		
2022	January 5	Change in PCR screening priorities and increased access to self-testing		
	January 17	Curfew lifted		
	January 31	Progressive easing of some of the measures		
	February 16	Vaccination passports no longer required for some public spaces		
	February 18	Booster dose offered to 12-17-year-olds (at least 3 months from the last dose)		
	February 21- March 7	Further easing of measures		

Supplementary table 2 Results of viral detection in patients hospitalised for acute respiratory infections in 2021-2022, 4 hospitals participating during pre-pandemic period and 2 additional hospitals

Number of patients and type of infection	2021-22 (4 main hospitals)	2021-22 (2 additional hospitals)
	Total number and detection rate, n(%)	Total number and detection rate, n(%)
Number of tested patients	1,170	594
	728(62.2%)	446(75.1%)*
At least one respiratory virus	, ,	` ,
Influenza, any	1(0.1%)	1(0.2%)
RSV	107(9.1%)	27(4.5%)*
Adenovirus	19(1.6%)	12(2.0%)
hMPV	15(1.3%)	33(5.6%)*
hPIV 1-4	7(0.6%)	7(1.2%)
hCoV	12(1.0%)	8(1.3%)
Entero/rhinoviruses	49(4.2%)	84(14.1%)*
Bocaviruses	9(0.8%)	2(0.3%)
SARS-CoV-2	380(32.5%)	196(33.0%)
Respiratory viruses without SARS-CoV-2		
Monoinfection	599(51.2%)	373(62.8%)*
Co-infections, any RV without SARS-CoV-2	98(8.4%)	55(9.3%)
SARS-CoV-2		
Monoinfection	349(29.8%)	178(30.0%)
Co-infections, SARS-CoV-2 + any RV	31(2.6%)	18(3.0%)

RSV: respiratory syncytial virus; hMPV: human metapneumovirus, hPIV: human parainfluenza viruses 1, 2, 3, and 4, hCoV: common human coronaviruses; RV: respiratory viruses; *P<0,0001